Erasca, Inc is recruiting patients for the clinical trial of ERAS-007 in Patients With Advanced or Metastatic Solid Tumors (HERKULES-1) (HERKULES-1).

The aim of Study BP41660 is to quantify the amount and concentration of [89Zr]DFO-RO7248824 in the brain with positron emission tomography (PET) following a single sub-pharmacological dose of RO7248824 and [89Zr]DFO-RO7248824 administered via IT injection to healthy participants.

The researchers plan that April 29, 2021 will be the study start date. The indicative completion of the clinical trial will be expected in January 5, 2022.

Among primary outcome measures are the Quantification of [89Zr]DFO-RO7248824 distribution within the central nervous system (CNS).

The study will take place at the Pra International Group B.V, Groningen, Netherlands.

The page dedicated to this clinical trial can be found here:


Clinical Research News

Upcoming Clinical Trials